These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 26626496)

  • 1. Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease.
    Junker AE; Gluud LL; van Hall G; Holst JJ; Knop FK; Vilsbøll T
    J Hepatol; 2016 Apr; 64(4):908-15. PubMed ID: 26626496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of incretin hormones and glucagon in patients with liver disease.
    Junker AE
    Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia.
    Junker AE; Gluud L; Holst JJ; Knop FK; Vilsbøll T
    J Intern Med; 2016 May; 279(5):485-93. PubMed ID: 26728692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.
    Bernsmeier C; Meyer-Gerspach AC; Blaser LS; Jeker L; Steinert RE; Heim MH; Beglinger C
    PLoS One; 2014; 9(1):e87488. PubMed ID: 24489924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct effect of GLP-1 infusion on endogenous glucose production in humans.
    Seghieri M; Rebelos E; Gastaldelli A; Astiarraga BD; Casolaro A; Barsotti E; Pocai A; Nauck M; Muscelli E; Ferrannini E
    Diabetologia; 2013 Jan; 56(1):156-61. PubMed ID: 23064290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.
    Camastra S; Astiarraga B; Tura A; Frascerra S; Ciociaro D; Mari A; Gastaldelli A; Ferrannini E
    Diabetes Obes Metab; 2017 Mar; 19(3):412-420. PubMed ID: 27898183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
    Nauck MA; Heimesaat MM; Behle K; Holst JJ; Nauck MS; Ritzel R; Hüfner M; Schmiegel WH
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1239-46. PubMed ID: 11889194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans.
    Meier JJ; Gethmann A; Götze O; Gallwitz B; Holst JJ; Schmidt WE; Nauck MA
    Diabetologia; 2006 Mar; 49(3):452-8. PubMed ID: 16447057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term aerobic exercise training improves gut peptide regulation in nonalcoholic fatty liver disease.
    Kullman EL; Kelly KR; Haus JM; Fealy CE; Scelsi AR; Pagadala MR; Flask CA; McCullough AJ; Kirwan JP
    J Appl Physiol (1985); 2016 May; 120(10):1159-64. PubMed ID: 27032902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Incretins-adipocytokines interactions in type 2 diabetic subjects with or without non-alcoholic fatty liver disease: interest of GLP-1 (glucagon-like peptide-1) as a modulating biomarker].
    Chellali S; Boudiba A; Griene L; Koceir EA
    Ann Biol Clin (Paris); 2019 Jun; 77(3):261-271. PubMed ID: 30998190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus.
    Hare KJ; Knop FK; Asmar M; Madsbad S; Deacon CF; Holst JJ; Vilsbøll T
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4679-87. PubMed ID: 19837930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.
    Schirra J; Nicolaus M; Roggel R; Katschinski M; Storr M; Woerle HJ; Göke B
    Gut; 2006 Feb; 55(2):243-51. PubMed ID: 15985560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.
    Liu Y; Wei R; Hong TP
    World J Gastroenterol; 2014 Jul; 20(27):9090-7. PubMed ID: 25083081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes.
    Halden TA; Egeland EJ; Åsberg A; Hartmann A; Midtvedt K; Khiabani HZ; Holst JJ; Knop FK; Hornum M; Feldt-Rasmussen B; Jenssen T
    Diabetes Care; 2016 Apr; 39(4):617-24. PubMed ID: 26908914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia.
    Ryan AS; Egan JM; Habener JF; Elahi D
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2399-404. PubMed ID: 9661618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1.
    Plamboeck A; Veedfald S; Deacon CF; Hartmann B; Vilsbøll T; Knop FK; Holst JJ
    Am J Physiol Regul Integr Comp Physiol; 2015 Sep; 309(5):R544-51. PubMed ID: 26136531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
    Hare KJ
    Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
    Christensen MB
    Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.
    Willms B; Idowu K; Holst JJ; Creutzfeldt W; Nauck MA
    Exp Clin Endocrinol Diabetes; 1998; 106(2):103-7. PubMed ID: 9628239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion.
    Hagemann D; Holst JJ; Gethmann A; Banasch M; Schmidt WE; Meier JJ
    Regul Pept; 2007 Oct; 143(1-3):64-8. PubMed ID: 17434608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.